Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT05683912

Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece

Conditions: Diabetic Macular Edema

Sex: All

Ages: 45 Years – N/A

Enrollment: 100

Sponsor: University of Athens

Location: Greece

Summary

ADMIRE was a prospective, observational cohort study of patients with diabetic macular edema (DME). Efficacy was assessed by change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to months 12, 24 and 36 after treatment with intravitreal aflibercept in treatment-naïve patients and previously treated patients. Safety was evaluated by recording any patients-reported events.

Eligibility Criteria

Inclusion Criteria:Patients with DM, able to give written informed consent Patients with DME>320 μm, who need treatmentExclusion Criteria:Patients with other retinal diseases than DME Intraocular surgery within the last 6 months

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05683912). StuddyBuddy aggregates publicly available trial information.